Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Algeta ASA

Division of Bayer AG
www.algeta.com

Latest From Aura Biosciences Inc.

Venture Funding Deals: New Cash For Delinia, Peloton, Fortis & Others

Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.

StartUps and SMEs Financing

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings

Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.

StartUps and SMEs Business Strategies

Out Of Stealth, Artax Hopes To Pioneer Nck Targeting In Autoimmune Disease

$10 million Series B will enable lead candidate AX-024 to advance into Phase IIa in undetermined autoimmune indications.

BioPharmaceutical United States

Venture Funding Deals, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Bayer AG
  • Senior Management
  • Andrew Kay, Pres. & CEO
    Roger Harrison, PhD, CBO
    Andreas Menrad, PhD, CSO
  • Contact Info
  • Algeta ASA
    Phone: (47) 23 00 79 90
    Kjelsasveien 172 A
    Kjelsas
    P.O. Box 54 Oslo, NO-0411
    Norway
Advertisement
Advertisement
UsernamePublicRestriction

Register